CUE BIOPHARMA INC (CUE) Stock Analyst Ratings
NASDAQ:CUE - Nasdaq - US22978P1066 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 85% to CUE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.57. This target is 364.84% above the current price.
CUE was analyzed by 8 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CUE.
In the previous month the buy percentage consensus was at a similar level.
CUE was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-04-02 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2024-08-20 | Stifel | Maintains | Buy -> Buy |
| 2024-07-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-07-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-04-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-09 | Stifel | Maintains | Buy -> Buy |
| 2024-04-03 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-03-13 | Jefferies | Initiate | Buy |
| 2023-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-06-15 | Stifel | Reiterate | Buy -> Buy |
| 2023-05-15 | JMP Securities | Reiterate | Outperform -> Outperform |
| 2023-03-22 | Oppenheimer | Reiterate | Outperform |
| 2023-03-22 | Stifel | Maintains | Buy |
| 2022-11-21 | Piper Sandler | Initiate | Overweight |
| 2022-08-24 | Oppenheimer | Maintains | Outperform |